STEGLUJAN

This brand name is authorized in Austria, Australia, Cyprus, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, United States

Active ingredients

The drug STEGLUJAN contains a combination of these active pharmaceutical ingredients (APIs):

1 Ertugliflozin UNII MLU731K321 - ERTUGLIFLOZIN PIDOLATE

Ertugliflozin helps to lower blood glucose by making the patient pass out glucose in the urine. It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys. Read about Ertugliflozin

2 Sitagliptin UNII TS63EW8X6F - SITAGLIPTIN PHOSPHATE

Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones. Read about Sitagliptin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
STEGLUJAN Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BD23	Metformin and ertugliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD23
A10BD24		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11561L, 11578J, 11579K, 11583P
Country: EE	Ravimiamet	Identifier(s): 1767988, 1767999, 1768002, 1768013, 1768024, 1768035, 1768046, 1768057, 1768068, 1768079, 1778878, 1778889
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 071784, 159405, 416330, 502790
Country: FR	Base de données publique des médicaments	Identifier(s): 64446015, 66301278
Country: HK	Department of Health Drug Office	Identifier(s): 66205, 66206
Country: IE	Health Products Regulatory Authority	Identifier(s): 43770, 43771
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8541, 8542
Country: IT	Agenzia del Farmaco	Identifier(s): 046342010, 046342022, 046342034, 046342046, 046342059, 046342073, 046342085, 046342097, 046342109, 046342111, 046342123, 046342147
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1085324, 1085325, 1085326, 1085327, 1085328, 1085329, 1085330, 1085331, 1085332, 1085333, 1085334, 1085335, 1085742, 1085743
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 167681, 167703
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100404697, 100404705
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66527001, W66527002, W66527003, W66528001, W66528002, W66528003, W66528004
Country: US	FDA, National Drug Code	Identifier(s): 0006-5367, 0006-5368